Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

This study looks at a new combination treatment for advanced melanoma that has been removed by surgery. It compares two drugs given together (nivolumab and relatlimab) against nivolumab alone, to see if the combination can help prevent the cancer from coming back.